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Evi-1 has been recognized as one of the dominant
oncogenes associated with murine and human mye-
loid leukemia. Here, we show that hematopoietic
stem cells (HSCs) in Evi-1-deficient embryos are se-
verely reduced in number with defective proliferative
and repopulating capacity. Selective ablation of Evi-
1 in Tie2+ cells mimics Evi-1 deficiency, suggesting
that Evi-1 function is required in Tie2+ hematopoietic
stem/progenitors. Conditional deletion of Evi-1 in the
adult hematopoietic system revealed that Evi-1-defi-
cient bone marrow HSCs cannot maintain hemato-
poiesis and lose their repopulating ability. In con-
trast, Evi-1 is dispensable for blood cell lineage
commitment. Evi-1+/ mice exhibit the intermediate
phenotype for HSC activity, suggesting a gene dos-
age requirement for Evi-1. We further demonstrate
that disruption of Evi-1 in transformed leukemic cells
leads to significant loss of their proliferative activity
both in vitro and in vivo. Thus, Evi-1 is a common
and critical regulator essential for proliferation of em-
bryonic/adult HSCs and transformed leukemic cells.
INTRODUCTION
The ecotropic viral integration site-1 (Evi-1) gene was first iden-
tified as a common locus of retroviral integration in myeloid tu-
mors in AKXD mice (Mucenski et al., 1988). In humans, Evi-1 is
located on chromosome 3q26, and rearrangements on chromo-
some 3q26 often activate Evi-1 expression in acute myeloid leu-
kemia (AML) and myelodysplastic syndrome (MDS) (Ogawa
et al., 1996; Suzukawa et al., 1994). Although these rearrange-
ments are infrequent in AML, they are of remarkable prognostic
value. Patients with these karyotypes are characterized by the el-
evated platelet count and lack of response to antileukemic ther-
apy (Pintado et al., 1985). Elevated Evi-1 expression occurs with
high frequency in AML patients without 3q26 abnormalities and
is also associated with unfavorable outcomes (Barjesteh van
Waalwijk van Doorn-Khosrovani et al., 2003; Valk et al., 2004).
Thus, Evi-1 is one of the key factors that predict poor survival
in leukemia patients.Evi-1 is amember of the SET/PR domain family of transcription
factors, and it contains a total of ten zinc finger motifs organized
in two discrete domains, located at the N terminus and toward
the C terminus, comprising seven (ZF1) and three (ZF2) repeats,
respectively, which have distinct DNA-binding specificities (Del-
wel et al., 1993; Perkins et al., 1991). The alternative forms gen-
erated from theEvi-1 gene include at least three distinct proteins:
Evi-1a, Evi-1b, and Evi-1c (MDS1-Evi-1) (Fears et al., 1996; Hirai,
1999; Figure 1A). Structurally in Evi-1c, a conserved PR domain
is located at the N terminus of the Evi-1a. Thus, PR-containing
(Evi-1c) and PR-absent (Evi-1a) forms of Evi-1 exist, both of
which are expressed in several developing and adult tissues. Al-
though related, functional differences between Evi-1a and Evi-1c
have been documented (Nitta et al., 2005; Sood et al., 1999). An-
other naturally occurring splice variant, designated Evi-1b, has
been described, which lacks 324 internal amino acids, including
zinc fingers 6 and 7 of ZF1 (Bordereaux et al., 1990). The biolog-
ical function of Evi-1b is not known thus far.
Previous studies revealed that Evi-1 possesses diverse func-
tions as an oncoprotein. Evi-1 antagonizes growth-inhibitory ef-
fects of transforming growth factor-b (TGF-b) by interacting with
Smad3 (Kurokawa et al., 1998); protects cells from stress-
induced cell death by inhibiting c-Jun N-terminal kinase (JNK)
(Kurokawa et al., 2000); increases the expression of endogenous
c-Jun and c-fos, resulting in activation of AP-1 (Tanaka et al.,
1994); and blocks granulocytic differentiation of myeloid cells
(Morishita et al., 1992). In addition, Evi-1 interacts with corepres-
sor CtBP, and this interaction contributes to Evi-1-mediated
repression of TGF-b signaling (Izutsu et al., 2001). Furthermore,
mouse models for Evi-1 overexpression have been established
using bone marrow infection and transplantation. These studies
showed that activation of Evi-1 in hematopoietic cells leads to
myeloid dysplasia while the development of full-blown leukemia
requires additional genetic events (Buonamici et al., 2004; Jin
et al., 2007).
The mutant mice with disrupted Evi-1 have been generated
(Hoyt et al., 1997). The homozygous embryos tend to exhibit
widespread hypocellularity, hemorrhaging, and disruption in
the development of paraxial mesenchyme, resulting in the death
in utero at approximately embryonic day 10.5 (E10.5). However,
these mice carry a targeted deletion of exon 7, resulting in an
isoform-specific null for the longer Evi-1 transcripts (Evi-1a and
Evi-1c), whereas the truncated form of Evi-1 (Evi-1b) remains
unaltered (Figure 1A). Therefore, the remaining expression of
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Regulation of Normal and Leukemic Cells by Evi-1Figure 1. Generation of Evi-1 Mutant Mice
(A) Schematic representation of Evi-1 isoforms. ZF1, zinc finger domain-1; ZF2, zinc finger domain-2; PR, PR domain.
(B) Schematic representation of gene targeting of the Evi-1 gene. E, EcoRV; S, SphI; neo/tk, PGK-neo/HSV-thymidine kinase positive selection cassette; DT-A,
diphtheria toxin A chain negative selection cassette.
(C) Southern blot analysis of SphI- (KO, knockout mice) or EcoRV- (cKO, conditional knockout mice) digested genomic tail DNA showing the predicted fragment-
length polymorphism.
(D) Expression of Evi-1 and b-actin protein in Evi-1+/+ and Evi-1/ embryos. Lysates were prepared from mouse embryo fibroblast (MEF) cells from E14.5
embryos and were analyzed by western blotting using anti-Evi-1 antibody (C50E12). *Nonspecific band.
(E) Genotypes of litters obtained by intercrossing Evi-1+/.
(F) Gross appearance of embryos at E16.5. The Evi-1/ embryo showed hemorrhaging with the yolk sac exhibiting severe anemia and defective large-vessel
development.208 Cell Stem Cell 3, 207–220, August 7, 2008 ª2008 Elsevier Inc.
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these mice.
In contrast to the established role of Evi-1 in leukemia develop-
ment, the role of Evi-1 in normal hematopoiesis has been poorly
understood. Recently, it was reported that Evi-1 is predomi-
nantly expressed in both embryonic and adult hematopoietic
stem cells (HSCs), and development of definitive HSCs in the
para-aortic splanchnopleural (P-Sp) region was severely im-
paired in Evi-1 mutant embryos (Yuasa et al., 2005). In addition,
several studies have shown that retroviral vector integration at
the Evi-1 locus can be related to long-term in vivo clonal domi-
nance without necessarily resulting in malignant transformation
in mice (Kustikova et al., 2005), nonhuman primates (Calmels
et al., 2005), and humans (Ott et al., 2006). These findings sug-
gest that Evi-1 has a role in the regulation of HSCs; however, fur-
ther functional analysis of Evi-1 has been hampered because of
the embryonic lethality of the Evi-1 mutant mice.
To further investigate the physiological role of Evi-1 in hemato-
poiesis, we created mutant mice in which exon 4 of the Evi-1
gene can be deleted by the expression of Cre recombinase, as
well as mice in which the same region was completely deleted.
Using thesemice, we here show that Evi-1 regulates proliferative
capacity of HSCs in a dose-dependent manner both during em-
bryogenesis and in adults. We further demonstrate that Evi-1 is
also required for proliferation of transformed leukemic cells,
and we provide candidate target genes of Evi-1 shared in
HSCs and leukemic cells.
RESULTS
Generation of Evi-1 Mutant Mice
The mutant mice of Evi-1 were previously generated by disrupt-
ing exon 7 of the Evi-1 gene (Hoyt et al., 1997); however, these
mice still retain the Evi-1b, and they lack the longer isoforms of
Evi-1 (Evi-1a and Evi-1c). Therefore, we targeted exon 4 of the
Evi-1 gene that is conserved in all of the known isoforms
(Figure 1A) and created mutant mice carrying deleted (Evi-1)
or loxP-flanked (Evi-1f) alleles (Figure 1B). Germline transmission
was confirmed by Southern blot analysis of tail DNA (Figure 1C).
Disruption of exon 4 of Evi-1 was confirmed by PCR and northern
blotting using RNA in embryos and by sequencing the amplified
PCR product of Evi-1/ embryo (Figures S1, S2, S3, and S4
available online). Immunoblotting of Evi-1/ embryo using three
different antibodies confirmed that all three isoforms of Evi-1
protein are absent in homozygous embryos (Figures 1D and S5).
C57BL/6 Mice Lacking Three Isoforms of Evi-1 Died
between E13.5 and E16.5
First, we analyzed our conventional Evi-1 knockout mice. Newly
generated Evi-1+/mice were born and were fertile, exhibiting no
morphological abnormalities. In contrast, Evi-1/ pupswere not
seen. To identify the stage of embryonic development at which
the Evi-1 mutation is lethal, E9.5–18.5 embryos were analyzed
for their genotype (Figure 1E). Surprisingly, our Evi-1/ mice
were alive with normal appearance at E10.5, when the previously
developed Evi-1 mutant mice died. After E13.5, many Evi-1/
embryos exhibited hemorrhaging and subcutaneous edema,
with the yolk sacs showing severe anemia and defective large-
vessel development (Figure 1F). Some Evi-1/ embryos sur-vived as long as E16.5 with comparable body size to wild-type
littermates, but no viable Evi-1/ fetuses were detected after
E18.5. Thus, our Evi-1/ mice lacking three isoforms of Evi-1
survived slightly longer than the prior Evi-1 mutant mice, but
they died between E13.5 and E16.5.
Decreased Hematopoietic Stem/Progenitor Cells
in Evi-1-Deficient Embryos
To assess the role of Evi-1 in hematopoiesis, we first examined
the capacity of definitive hematopoiesis in Evi-1/ embryos,
which occurs in the P-Sp region at E9.5, using an in vitro P-Sp
explant/OP9 stromal cell coculture system (Goyama et al.,
2004). Consistent with the findings obtained for the prior Evi-1
mutant mice (Yuasa et al., 2005), the number of HSCs in the
Evi-1/ P-Sp cultures was significantly decreased in compari-
son to the number of HSCs in the wild-type controls
(Figure 2A). We next assessed fetal liver (FL) hematopoiesis in
Evi-1+/ and Evi-1/mice. The Evi-1/ FL contained nucleated
erythrocytes, granulocytes, and B-lymphocytes and was mor-
phologically indistinguishable from the wild-type FL (Figures
2B and S6). However, the population of lineage, c-Kit+,
Sca-1+ cells (LSK cells) or lineage, c-Kit+, CD34+ cells, which
enriches hematopoietic stem/progenitor cells, was severely re-
duced in Evi-1/ mice. The Evi-1+/ FL showed an intermedi-
ated phenotype (Figure 2B). The total number of colony-forming
cells (CFCs), especially the number ofmixed colonies, inEvi-1/
FL cells was also severely decreased (Figure 2C). Together,
these results suggest that Evi-1 deletion causes severe reduc-
tion in hematopoietic stem/progenitor cells but is compatible
with differentiation of progenitors once they are formed.
Defective HSC Activity in Evi-1-Deficient Embryos
To determine whether Evi-1/ embryos possess functional
HSCs, we tested the ability of Evi-1/ FL cells to reconstitute
the hematopoietic system of recipient mice. FL cells (2 3 106
cells) from E14.5 wild-type or Evi-1/ embryos were injected
into lethally irradiated (9.5 Gy) recipient mice. All recipients re-
ceiving wild-type FL cells survived and remained healthy for at
least 1 month; however, no recipients receiving donor cells
from Evi-1/ embryos survived beyond 2 weeks (Figure 2D).
We further performed the competitive reconstitution assay. FL
cells (1 3 106 cells) from wild-type or Evi-1/ (Ly5.2) embryos
were injected into lethally irradiated recipient mice (Ly5.1) to-
gether with 2 3 105 competitor bone marrow (BM) cells from
wild-type mice (Ly5.1). Evi-1/ cells were not detected at all in
the recipient mice either 4 or 16 weeks after transplantation. In
contrast, wild-type FL cells reconstituted hematopoiesis of the
recipients to a larger extent than competitor cells (Figures 2E
and S7). Thus, Evi-1 is required for HSC activity to reconstitute
the hematopoietic system in recipients.
Deletion of Evi-1 in Tie2+ Cells Mimics Evi-1 Deficiency
Next, we crossed Evi-1f/f mice with Tie2-Cre mice (Li et al., 2006)
to selectively disrupt Evi-1 function in Tie2+ endothelial and he-
matopoietic stem/progenitor cells. Most of Tie2-Cre+;Evi-1f/f
embryos died around E13.5 to E16.5 with hemorrhage and/or
subcutaneous edema, as Evi-1-deficient embryos do (Figures
3A and 3B). A few Tie2-Cre+;Evi-1f/f mice were born alive and
grew to adults (Figure 3A), but BM of these mice primarily
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(A) Flow cytometric profiles of the cells from the P-Sp cultures harvested after 5 days in culture. (Aa) CD45+ cells in P-Sp culture were gated. (Ab) CD45+ cells were
examined for the expression of CD34 and c-Kit. (Ac) The numbers of CD45+, CD34+, c-Kit+ hematopoietic stem/progenitor cells in P-Sp culture derived from
wild-type or Evi-1/ mice. n = 3. ***p = 0.0001.
(B) Flow cytometric profiles of wild-type, Evi-1+/, and Evi-1/ littermate FL at E14.5. (Ba and Bb) Population of hematopoietic stem/progenitor cells. (Bc) Quantifi-
cationof flowcytometric analysis.Data aremean±SDfrom fourmice. P valueswerecalculatedascomparedwithwild-typeembryos. **p=0.0043. ***p<0.0001. (Bd)
Population ofmyeloid and erythroid cells. (Be) Population of B-lymphocytes. Numbers of eachpanel represent percentagesof the gated population inwhole FL cells.
(C) CFCs in wild-type, Evi-1+/, and Evi-1/ littermate FL cells. p values were calculated as compared with wild-type embryos. n = 4. **p = 0.0009.
(D) Survival curve of lethally irradiated recipients receiving either wild-type or Evi-1/ FL cells.
(E) Competitive repopulation assays. (Ea) Flow cytometric analysis of peripheral blood cells at 4 weeks after transplantation show extensive contribution of wild-type
FL cells (Ly5.2), but no detectable contribution of Evi-1/ cells. (Eb) Cumulative data of donor contribution in peripheral blood of recipients 4 weeks after transplan-
tation. n = 6. Data are mean ± SD.
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consisted of cells that retain the nonexcised Evi-1f allele
(Figure 3C), indicating that hematopoiesis originated from cells
that had escaped Cre-mediated excision. HSCs and CFCs
were severely decreased in the FL of Tie2-Cre+;Evi-1f/f embryos
(Figures 3D, 3E, and S8). Thus, selective ablation of Evi-1 in Tie2+
cells virtually reproduced all of the phenotypes of Evi-1/ mice,
Figure 3. Selective Ablation of Evi-1 in Tie2+ Cells
(A) Genotypes of litters obtained by intercrossing Tie2-Cre;Evi-1f/+ and Evi-1f/+ mice.
(B) Gross appearance of E16.5 fetuses. Tie2-Cre;Evi-1f/f embryo are edematic and show hemorrhaging.
(C) Southern blot genotyping of FL cells (E14.5) and BM cells (1 month after birth). Evi-1 was excised efficiently in E14.5 fetal liver cells of Tie2-Cre;Evi-1f/f em-
bryos, but BM cells of the surviving Tie2-Cre;Evi-1f/f mice exclusively harbored nonexcised Evi-1 allele.
(D) CFCs in Tie2-Cre;Evi-1+/+, Tie2-Cre;Evi-1f/+, Tie2-Cre;Evi-1f/f littermate FL cells. p values were calculated as compared with Tie2-Cre;Evi-1+/+ embryos. n = 2.
*p = 0.0108.
(E) (Ea) Population of hematopoietic stem/progenitors in Tie2-Cre;Evi-1+/+, Tie2-Cre;Evi-1f/+, Tie2-Cre;Evi-1f/f littermate FL cells (E14.5). Numbers of each panel
represent percentages of the gated population in whole FL cells. (Eb) Quantification of flow cytometric analysis. Data are mean ± SD from twomice. p values were
calculated as compared with Tie2-Cre;Evi-1+/+ embryos. (LSK) *p = 0.0077. **p = 0.0041. (CD34+-LK) *p = 0.0113. **p = 0.002.
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development and proliferation of HSCs.
Evi-1 Is Essential for Proliferation/Maintenance of Adult
BM HSCs
To assess a role of Evi-1 in adult hematopoiesis, we then crossed
Evi-1f/f micewithMx-Cre transgenicmice, in which a high level of
Cre recombinase is produced by treatment with the interferon in-
ducer pI-pC, leading to recombination in hematopoietic cells of
all lineages. Injection of pI-pC did not cause significant differ-
ences in white blood cell (WBC) counts or hemoglobin levels
among the Mx-Cre;Evi-1f/f (Evi-1-excised), Mx-Cre;Evi-1+/+,
and Evi-1f/f mice, and the platelet counts in the Evi-1-excised
mice modestly declined compared with those in control mice 4
weeks after pI-pC injection (Figure 4A). We next examined the ef-
fect of Evi-1 deletion in various hematopoietic cell populations.
By 4 weeks after pI-pC injection, Evi-1-excised mice exhibited
significant decrease in the frequency of HSCs and CFCs com-
pared with control mice (Figures 4B and S9). In contrast, the
frequencies of mature myeloid cells (Gr-1+ or Mac-1+ cells),
B-lymphocytes (B220+ cells), and T-lymphocytes (CD3+, CD4+,
or CD8+ cells) did not appear to be affected (Figure S10) in spite
of the efficient excision of Evi-1 alleles in a majority of these cells
(Figure 4C, upper panel). Interestingly, by 12 weeks after pI-pC
injection, cells in all hematopoietic populations contained
primarily the nonexcised Evi-1f allele (Figure 4C, lower panel).
These results indicate that HSCs can not maintain hematopoie-
sis in the absence of Evi-1, and it is likely that a small fraction of
HSCs that escaped Cre-mediated Evi-1 excision expand and
predominate over Evi-1-deficient HSCs.
We further assessed a role of Evi-1 for the hematopoietic re-
constitution in BM progenitors using Cre-encoding retroviruses.
BM progenitors were harvested from wild-type (Ly5.2) or Evi-1f/f
(Ly5.2) mice and then infected with GFP (control) or Cre-GFP ex-
pressing retrovirus. Evi-1 is completely deleted only in the GFP+,
Cre-transduced fraction of Evi-1f/f BM progenitors (Figure 4D).
We then injected these progenitors into sublethally irradiated
(6.5 Gy) recipient mice (Ly5.1) and assessed the frequency of
GFP+ fraction in donor (Ly5.2) cells 2 weeks after transplantation.
The infection efficiency among all three groups was similar be-
fore transplantation. Remarkably, we found a profound loss of
GFP+ cells in Cre-transduced Evi-1f/f BM progenitors after trans-
plantation, although a modest Cre-induced stasis was observed
in wild-type BM progenitors (Figure 4D). Taken together, these
results suggest that Evi-1 is indispensable for proliferation/main-
tenance of adult BMHSCs, yet it is dispensable for differentiation
into myeloid, erythroid, and lymphoid lines.
Haploinsufficiency of Evi-1 Perturbs Adult HSC
Homeostasis
We then analyzed hematopoiesis of Evi-1+/ mice that survive
through adulthood without overt abnormalities. Mature blood
cell counts in peripheral blood of Evi-1+/mice were comparable
to those of wild-type mice (Figure S11). However, Evi-1+/ mice
had a lower abundance of LSK and CD34LSK cells, which in-
clude short-term and long-term HSCs (Figure 5A). Therefore,
we evaluated HSC function by testing the ability of Evi-1+/ BM
cells to competitively repopulate the adult hematopoietic com-
partment in lethally irradiated recipient mice. BM cells from
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planted into lethally irradiated Ly5.1 mice together with wild-type
competitor Ly5.1 BM cells at a ratio of 1:1 or 1:10 of test cells to
competitor cells. The average contribution of Evi-1+/ donor
BM cells to total peripheral blood cells was lower than that of
wild-type controls at 4 and 16 weeks after transplantation
(Figure 5B). These results, together with the observation that
Evi-1+/ FL had a reduced number of HSCs, suggest a gene dos-
age requirement for Evi-1 in the regulation of HSCs.
Delayed Hematopoietic Recovery after 5FU Treatment
in Evi-1+/ and Evi-1-Excised Mice
To assess the effect of Evi-1 dose in the kinetics of hematopoi-
etic recovery after myelosuppressive treatment, we adminis-
tered a single dose of 5FU to wild-type and Evi-1+/mice and se-
rially followed peripheral blood counts. As shown in Figure 5C,
Evi-1+/mice showed a significant delay in the platelet recovery.
We performed the same experiment using Mx-Cre;Evi-1f/f, Mx-
Cre;Evi-1+/+, and Evi-1f/f mice 7 days after pI-pC injection and
also found that platelet recovery was significantly delayed in
Evi-1-excised mice (Figure 5C). These results indicate that Evi-
1 has a specific role in platelet formation. Alternatively, perturba-
tion of HSC compartment in Evi-1+/ and Evi-1-excised mice
may have a stronger influence on platelet recovery than on the
recovery of other lineages. The recovery of HSCs after 5FU ad-
ministration in Evi-1-excised mice was also delayed, and the re-
covered HSCs in Evi-1-excised mice possessed primarily the
nonexcised Evi-1f allele (Figure 5D). Thus, Evi-1 is required for
the efficient recovery of HSCs and platelets after myelosuppres-
sive treatment.
Consequences of Evi-1 Deletion on Cell Viability and
Proliferation
To characterize the defective proliferation capacity of hemato-
poietic stem/progenitors in Evi-1-excised mice, we assessed
proliferation in vitro using a culture system that expands BM
HSCs (Zhang and Lodish, 2005). BM progenitors derived from
control (Evi-1f/f) or Evi-1-excised (Mx-Cre;Evi-1f/f) mice were
cultured in serum-free medium containing SCF, TPO, IGF2,
and FGF-1. We found that Evi-1-excised progenitors exhibited
reduced proliferation relative to controls (Figure 6A). Cell-cycle
and apoptosis analysis at day 15 of culture revealed a significant
decrease in the proportion of S/G2/M phase cells and an in-
crease in the percentage of Annexin-V-positive cells for Evi-1-
excised cells (Figures S12 and S13). Accelerated apoptosis
and impaired cell cycling will explain the attenuated proliferation
of Evi-1-excised cells in this culture condition. We then excised
Evi-1 in vitro using Cre-encoding retroviruses. BM progenitors
were harvested from wild-type or Evi-1f/f mice and infected
with GFP (control) or Cre-GFP-expressing retroviruses. These
progenitors were cultured in the condition as described above
and assessed the frequency of GFP+ fraction every 5 days.
This approach also revealed reduced proliferation of GFP+ cells
in Cre-transduced Evi-1f/f (Evi-1-excised) progenitors (Figures
6B and S14). Taken together, we concluded that Evi-1 is required
for sustaining cytokine-dependent proliferation of hematopoietic
stem/progenitors.
We next assessed in vivo cell-cycle distribution of FL or BM
cells derived from control (Evi-1f/f) or Evi-1-excised (Mx-Cre;
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(A) Peripheral blood cell counts of Mx-Cre;Evi-1+/+, Evi-1f/f, and Mx-Cre;Evi-1f/f mice injected with pI-pC on weeks 0, 4, and 8. Results are shown as mean ± SD
from three (controls) to eight (Mx-Cre;Evi-1f/f) mice. p values were calculated as compared with controls. *p = 0.0004.
(B) Flow cytometric analysis of Evi-1f/f or Mx-Cre;Evi-1f/f mice 4 weeks after pI-pC injection. (Ba) Population of HSCs in the BM. Numbers of each panel represent
percentages of the gated population in whole BM. (Bb) Quantification of flow cytometric analysis. n = 3. Data are mean ± SD. *p = 0.015. **p = 0.0031.
(C) PCR genotyping of cells from various hematopoietic populations of Mx-Cre;Evi-1ff mice 4 weeks (upper panel) and 12 weeks (lower panel) after pI-pC injec-
tion. Efficient excision of Evi-1 was observed at 4 weeks, but cells in all populations at 12 weeks primarily harbored nonexcised Evi-1 allele.
(D) (Da) Infection efficiencies before transplantation were compatible among three groups, but GFP+ fraction in Cre-transduced Evi-1ff BM cells (Evi-1-excised
cells) disappeared after transplantation. (Db) Relative ratios of GFP+ fraction in Ly5.2 donor cells after transplantation compared with those before transplanta-
tion. Data are shown asmean ± SD from three independent experiments. Each group contains six mice. ***p < 0.0001. (Dc) PCR analysis of flanked Evi-1 alleles in
control and Cre-transduced BM cells. The flanked Evi-1 alleles became undetectable in GFP+, Cre-transduced Evi-1f/f BM cells.
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(A) (Aa) Evi-1+/BMexhibited significant decrease in the size of the short-term (ST)-HSC (lin, Sca-1+, c-Kit+) and long-term (LT)-HSC (CD34, lin, Sca-1+, c-Kit+)
compartments. (Ab) Quantification of flow cytometric analysis on the size of ST- and LT-HSCs of wild-type and Evi-1+/ mice. n = 4. Data are mean ± SD
*p = 0.0056. **p = 0.0041.
(B) Competitive transplantation reveals diminished repopulating ability of Evi-1+/ BM. n = 4. Data are shown as mean ± SD. 1:1, *p = 0.03242. 1:10, **p = 0.0028,
***p = 0.0005.
(C) Peripheral blood cell recovery after 5FU treatment was followed by serial peripheral blood count monitoring of mice. (Ca) Wild-type and Evi-1+/ mice. n = 4.
**p = 0.0091. (Cb) Mx-Cre;Evi-1+/+, Evi-1f/f, andMx-Cre;Evi-1f/f mice 7 days after induced deletion of the floxed genes. p values were calculated as comparedwith
controls. n = 4. **p = 0.0012.
(D) HSC recovery after 5FU treatment of Evi-1f/f andMx-Cre;Evi-1f/f mice. HSC recovery wasmodestly delayed in Evi-1-excisedmice, and re-emerging HSCs had
primarily harbored nonexcised Evi-1 allele. Similar results were obtained in three independent experiments.
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(A) Lineage, c-Kit+ cells were purified from Evi-1f/f or Mx-Cre; Evi-1f/f mice 3–4 weeks after Cre induction. Cells were cultured in liquid medium containing SCF,
TPO, IGF-2, and FGF-1. Total cell numbers were monitored every 5 days. Five independent experiments were performed in each group.
(B) BM progenitors derived from wild-type or Evi-1f/f mice were transduced with GFP or Cre-GFP retrovirus and were cultured as in (A). The frequency of GFP+
fraction was assessed every 5 days. Four or five independent experiments were performed in each group. *p = 0.0108. **p = 0.0061.
(C) Cell-cycle status was assessed in various hematopoietic populations of E14.5 FL cells (Ca), BM cells at day 8 post Cre induction (Cb), and BM cells at day 21
post Cre induction (Cc). Evi-1-excised FL cells and BM cells at day 8 post Cre induction exhibited normal cell-cycle distribution relative to littermate controls, but
Evi-1-excised CD34LSK cells at day 21 post Cre induction showed an increased frequency of S/G2/M phase cells. **p = 0.0015.
(D) Apoptosis was assessed using Annexin-V staining. (Da) Evi-1-excised FL cells exhibited an increased frequency of Annexin-V+ cells. (Db and Dc) Evi-1-ex-
cised BM cells exhibited normal frequency of apoptotic cells both at days 8 and 21 after Cre induction. **p = 0.004 (MNC). p = 0.0021 (c-Kit[+]). MNC, mono-
nuclear cells; Lin, lineage.Evi-1f/f) mice. We found a significant increase in S/G2/M phase
CD34LSK cells in Evi-1-excised BM 21 days after Cre induc-
tion. In contrast, no difference in cell-cycle distribution was de-tected in Evi-1-excised BM cells immediately after Cre induction
(at day 8). Furthermore, Evi-1 deletion had no effect on the cell-
cycle distribution of FL cells (Figure 6C). Therefore, the increased
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pacity of Transformed Leukemic Cells
(A) Schematic representation of the following ex-
periments. BM progenitors from wild-type or Evi-
1f/f mice were transduced with MLL/ENL or E2A/
HLF oncogenes. Immortalized cells from the third
to fifth round of in vitro plating were subsequently
transduced with either GFP- or Cre-GFP-express-
ing retrovirus. GFP+ cells were sorted, and then
relative clonogenic activity was assessed in the
additional round of plating.
(B) Relative numbers of colonies generated by
Cre-transduced cells compared with GFP-trans-
duced cells. Deletion of Evi-1 significantly attenu-
ated clonogenic activities of MLL/ENL and E2A/
HLF-transformed cells to 28% and 58% of the
controls. Data are shown as mean ± SD from three
(MLL/ENL) and four (E2A/HLF) independent ex-
periments. *p = 0.0322. ***p = 0.0001.
(C) Schematic representation of the following
experiments. BM progenitors from wild-type or
Evi-1f/f mice were transduced with cMyc-bcl2
in combination with GFP or Cre-GFP. Infected
progenitors were transplanted into recipients.
(D) Survival curves of mice transplanted with wild-
type or Evi-1f/f progenitors transduced by cMyc-
bcl2 + GFP or Cre-GFP. Each group contains 10
or 11 mice.
(E) Relative ratios of GFP+ fraction in leukemic
cells after transplantation compared with those
before transplantation. Peripheral blood cells
were isolated from moribund mice, and the fre-
quencies of the GFP+ cells were assessed. Data
are shown as a boxplot.
(F) Expression patterns of putative target genes of
Evi-1 in cases with AML. Areas of each circular
graph represent the percentages of genes exhibit-
ing a similar or opposite expression pattern to that
of Evi-1 in AML samples. Results are depicted as
for two independent probes (215851 and
221884) used for evaluation of Evi-1 expression.number of cycling Evi-1-excised HSCs at day 21 is probably due
to the depletion of quiescent BM HSCs rather than the direct
effect of Evi-1 deletion. We then assessed apoptosis in FL or
BM cells by Annexin-V-binding to cell surface. Evi-1 deletion sig-
nificantly increased the rate of cell death in FL cells. However, no
significant difference was noted in the percentage of Annexin-V-
positive cells in control or Evi-1-excised BM cells (Figure 6D).
Therefore, the increased cell death would contribute to the de-
fective proliferation of Evi-1-excised FL cells but did not account
for the homeostasis defects of Evi-1-excised BM HSCs. Thus,
the effects of Evi-1 deletion on cell cycling and viability in vivo
vary in a context-dependent manner.
Evi-1 Is Required for Efficient Propagation of
Transformed Leukemic Cells
Next, we evaluated a role for Evi-1 in myeloid transformation.
MLL/ENL (ME) and E2A/HLF (EH) are chimeric genes gener-
ated in t(11;19) and t(17;19) leukemias, respectively, both of
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lecular mechanisms, resulting in sustained colony formation in
the serial replating assay (Ayton and Cleary, 2003; Smith et al.,
2002). BM progenitors were harvested from wild-type or Evi-1f/f
mice and then transduced with ME or EH. After establishment
of sustained clonogenic activity following more than three
rounds of replating in methylcellulose medium, the cells were
transduced with GFP or Cre-GFP-expressing retroviruses.
Then, GFP+ cells were sorted and subjected to another round
of replating to evaluate relative clonogenic activity (Figure 7A).
Disruption of Evi-1 inME-transformed progenitors caused signif-
icant reduction in colony numbers to about 30% of the control,
whereas Cre expression in ME-transformed wild-type progeni-
tors resulted in marginal decrease of clonogenic activity. Evi-1
deletion also modestly reduced clonogenic activity in EH-trans-
formed cells to about 60% of the control (Figure 7B).
We next examined a role for Evi-1 in in vivo leukemia develop-
ment using transplantation of the cells transduced by cMyc-bcl2
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model is useful for evaluating the in vivo effects of Evi-1 deletion
on the leukemogenetic activity because these mice developed
leukemia with very short latencies. BM progenitors purified
from wild-type or Evi-1f/f mice were cotransduced with cMyc-
bcl2 together with GFP or Cre-GFP-expressing retroviruses.
We then injected these progenitors (1 3 106) into recipient
mice and assessed their survival (Figure 7C). All the recipient
mice developed leukemia as described previously (Luo et al.,
2005; Figure S15); however, themice transplanted with Evi-1-ex-
cised cells died with significantly longer latencies (Figure 7D).
Furthermore, we found significant loss of GFP+ cells in the pe-
ripheral blood of the leukemic mice transplanted with cMyc-
bcl2- and Cre-transduced Evi-1f/f (Evi-1-excised) progenitors,
suggesting impaired contribution of Evi-1-excised cells to leuke-
mia, although a modest Cre-induced stasis was observed as for
wild-type progenitors (Figure 7E). We also used the two-step
transplantation model to assess the effect of Evi-1 deletion on
the maintenance of leukemia. We first transplanted wild-type
or Evi-1f/f progenitors transducedwith cMyc-bcl2 into recipients.
Leukemic cells were then isolated from the spleens of moribund
primary cMyc-Bcl2 mice, and the cells were transduced with
GFP or Cre-GFP-expressing retroviruses. Then, the GFP+ cells
were sorted and transplanted into secondary recipients to eval-
uate the leukemogenic activity (Figure S16). This approach again
demonstrated that the mice transplanted with Evi-1-excised leu-
kemic cells died with significantly longer latencies (Figure S17).
Thus, Evi-1 is required for efficient propagation of transformed
leukemic cells both in vitro and in vivo.
Putative Target Genes of Evi-1 in HSCs and AML
Samples
To identify the common target genes of Evi-1 shared in HSCs
and leukemic cells, we first carried out genome-wide transcrip-
tional analysis using GFP or Cre-GFP-infected Evi-1f/f HSCs.
LSK cells derived from Evi-1f/f mice were transduced with GFP
or Cre-GFP-expressing retroviruses, and GFP+ cells were
sorted. Evi-1 deletion in Cre-GFP-transduced cells was con-
firmed by PCR (Figure S18). Linear amplification of RNAobtained
fromGFP+ cells and subsequent gene-expression profiling iden-
tified 378 downregulated and 446 upregulated genes in Evi-1-
deleted HSCs. Transcripts were considered upregulated or
downregulated if the change in transcript level as a multiple of
the control was >1.2. We then assessed the correlation between
expression of Evi-1 and these potential target genes in AML
samples using gene-expression data of 285 individuals with
AML (Valk et al., 2004; Figure S19). We found that expression
of the genes activated by Evi-1 in HSCs tends to coincide with
that of Evi-1 in AML samples, whereas many of the genes re-
pressed by Evi-1 in HSCs showed an expression pattern oppo-
site to that of Evi-1 in AML (Figure 7F). Thus, our approach re-
vealed the existence of the common regulatory pathway
underlying Evi-1-mediated hematopoiesis and leukemogenesis
and provides putative target genes of Evi-1 in both HSCs and
leukemic cells. The potential Evi-1 target genes include genes
whose expression is decreased in the Evi-1/ P-Sp region
(Gata1, Gata2, and Angpt1) (Yuasa et al., 2005), genes involved
in the regulation of HSCs (Gata2, Angpt1, Mpl, Jag2, Pbx1, and
Setbp1), and genes related to platelet formation (Gata1, Mpl,Itga2b, and Itgb3) (Tables S1 and S2). We evaluated the expres-
sion levels of some of the putative target genes of Evi-1 in LSK
cells transduced with GFP or Cre-GFP using quantitative PCR
method, and we found that they showed a similar tendency to
the results obtained by the microarray analysis (Figure S20).
DISCUSSION
Although Evi-1 has been recognized as a crucial gene that pro-
motes leukemogenesis, a physiological role of Evi-1 in vivo, par-
ticularly in terms of adult hematopoiesis, is poorly understood. In
this study, we generated Evi-1mutantmice and showed that Evi-
1 is a common regulator essential for proliferation of hematopoi-
etic stem/progenitor cells both during fetal development and in
adults. Evi-1 function is required for establishment of definitive
HSCs in Tie2+ cells of developing embryos. Furthermore,
Evi-1+/ mice exhibited the intermediate phenotype as for the
number of HSCs, as well as hematopoietic reconstitution activity
of the BM cells, suggesting a gene dosage requirement for Evi-1
in the regulation of HSCs. We also found that the platelet counts
modestly declined in Evi-1-excised mice, and platelet recovery
after the myelosuppressive treatment was significantly delayed
in Evi-1+/ and Evi-1-excised mice. Although the underlying
mechanism responsible for this defective platelet formation re-
mains to be identified, this phenotypemay reflect the clinical fea-
ture of elevated platelet counts in AML/MDS cases carrying 3q26
rearrangements.
The Evi-1/ mice we have created survived longer than the
previously developed Evi-1 mutant mice. In the prior Evi-1
mutant mice, the expression of Evi-1b (shorter isoform) is unaf-
fected. In addition, the previous Evi-1 knockout was established
with ES-D3 cells with chimeras subsequently mated to CF-1
mice. Therefore, both the presence of Evi-1b in the prior Evi-1
mutant mice and dissimilar genetic backgrounds may contribute
to the different stages of death.
An emerging concept in the field of cancer biology is that a rare
population of ‘‘cancer stem cells’’ exists among the heteroge-
neous group of cancer cells (Bonnet and Dick, 1997). Cancer
stem cells have the abilities to self-renew and differentiate into
multiple cell types, and these cells persist in tumors as a distinct
population that likely causes disease relapse. Therefore, elimina-
tion of the cancer stem cell compartment is necessary and po-
tentially sufficient for cure of the cancer. Several factors that gov-
ern the fate of adult stem cells also play a significant role in the
regulation of cancer stem cells, such as Wnt, Notch, hedgehog,
and Bmi-1 (Huntly and Gilliland, 2005; Lessard and Sauvageau,
2003). Of note, retrovirus-induced Evi-1 activation in hematopoi-
etic cells leads to long-term in vivo clonal dominance of the in-
fected cells (Calmels et al., 2005; Kustikova et al., 2005; Ott
et al., 2006), and elevated expression of Evi-1 is associated
with poor treatment outcomes in leukemia patients (Barjesteh
van Waalwijk van Doorn-Khosrovani et al., 2003; Valk et al.,
2004). Therefore, together with the findings in this report, we hy-
pothesized that activation of Evi-1 enhances proliferation/sur-
vival of leukemia stem cells and, thus, confers drug resistance
on various types of leukemia. In support of this is our observation
that Evi-1 deletion in transformed leukemic cells leads to signif-
icant loss of their proliferative activity both in vitro and in vivo.
Therefore, it is tempting to speculate that Evi-1 induces leukemia
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newing capacity in leukemic cells. Consequently, therapies de-
signed to target Evi-1 will be an attractive option in the treatment
of leukemia patients, especially in the treatment of those with
a poor prognosis.
The presence of zinc fingers that are able to bind to specific
sequences of DNA suggests that Evi-1 is a transcriptional regu-
lator; however, target genes of Evi-1 have been poorly identified
thus far. Here, we identified candidate Evi-1 target genes using
gene-expression-profiling analysis in HSCs combined with the
gene-expression data of AML samples. Our analysis revealed
the existence of common target genes of Evi-1 in HSCs and leu-
kemic cells. Notably, many genes involved in the HSC regulation,
including Gata2, Angpt1,Mpl, Jag2, Pbx1, and Setbp1, are acti-
vated by Evi-1, implying that Evi-1 acts as a key regulator in
HSCs and leukemic cells. Although it has yet to be determined
whether these are primary targets of Evi-1, these data provide
a starting point for further studies to uncover the underlying
mechanisms for Evi-1-mediated hematopoiesis and leukemo-
genesis.
Finally, the functions of Evi-1 that we identified in the current
study provide an insight into homeostasis and malignant trans-
formation of various types of organs other than the hematopoi-
etic system. Evi-1 is expressed in several other organs, including
kidney and ovary (Morishita et al., 1990). Furthermore, aberrant
expression of Evi-1 has been frequently found in a variety of solid
tumors (Sugita et al., 2000). Thus, Evi-1 may play an important
role in stem cell regulation and cancer development in a broad
spectrum of tissues.
EXPERIMENTAL PROCEDURES
Mice
Evi-1 mutant mice were generated as described in the Supplemental Experi-
mental Procedures. For conditional deletion of Evi-1 in vivo, mice possessing
the Evi-1f allele were mated to Tie2-cre or Mx-cre transgenic mice. Mx-cre
expression was induced by intraperitoneally injecting 500 mg of pIpC, on
3 alternate days, into 6- to 8-week-old mice. Times after pI-pC injection are
counted from the first day of injection. Competitive repopulation assay was
performed using the Ly5 congenic mouse system. Mice were kept at the
Animal Center for Biomedical Research, University of Tokyo, according to
institutional guidelines.
Flow Cytometric Analysis
A list of antibodies is provided in the Supplemental Experimental Procedures.
Cells were sorted with a FACSAria, and analysis was performed on
FACSCaliber or LSRII (BD Biosciences). To analyze the cell-cycle status, cells
were first stained with lineage and stem/progenitor markers, followed by
staining with 10 ng/ml Hoechst 33342 at 37C for 75 min. Apoptosis was
assayed by staining cells with lineage and stem/progenitor markers, followed
by Annexin-V and propidium iodide (PI) staining.
P-Sp Culture
P-Sp culture was performed as described previously (Goyama et al., 2004).
Colony-Forming Assay
Colony-forming assay was performed in MethoCult GF M3434 (Stem Cell
Technologies) with 2 3 104 FL or BM cells and scored for mixed, myeloid,
erythroid colony formation at 7 days.
Retrovirus Production
To produce oncoprotein-expressing retrovirus, Plat-E packaging cells (Kita-
mura et al., 2003) were transiently transfected with retroviral constructs (see
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(Goyama et al., 2004). To produce GFP- or Cre-GFP-expressing retrovirus,
we used cMP34 packaging cells (Takara) transduced with pGCDNsam-
eGFP or pGCDNsam-eGFP-iCre.
Transplantation Assays
For FL transplantation, FL cells from E14.5 wild-type or Evi-1/ embryos (both
Ly5.2) alone (noncompetitive transplants) or mixed with BM cells from wild-
typemice (Ly5.1) (competitive transplants) were injected into lethally irradiated
(9.5 Gy) recipient mice (Ly5.1). For BM transplantation using Cre-expressing
retrovirus, c-Kit+ BM progenitors from wild-type or Evi-1f/f mice (Ly5.2) were
transduced with GFP- or Cre-GFP-expressing retroviruses and injected into
sublethally irradiated (6.5 Gy) recipients (Ly5.1). For competitive transplanta-
tion using wild-type or Evi-1+/ BM cells, nucleated BM cells (Ly5.2) from
each genotype were admixed in 1:1 or 1:10 ratio with competitor BM cells
(Ly5.1) and injected into lethally irradiated (9.5 Gy) recipients (Ly5.1).
5FU Treatment
We used 5FU (200 mg/kg, i.p.) for myelosuppression. Peripheral blood cell
counts were monitored every 5 days in each mouse.
BM Culture Assays
Lineage, c-Kit+ BM progenitors were plated at a density of 105/ml in Stem-
Span serum-free medium (StemCell Technologies) supplemented with
10 mg/ml heparin, 10 ng/ml mouse SCF, 20 ng/ml mouse TPO, 20 ng/ml mouse
IGF-2, and 10 ng/ml human FGF-1. Cell counts were monitored every 5 days.
For the culture using Cre-expressing retroviruses, c-Kit+ BMprogenitors trans-
duced with GFP or Cre-GFP were cultured in the identical condition.
Myeloid Progenitor Transformation Assays
BM progenitors (c-Kit+ cells) from wild-type or Evi-1f/f mice were transduced
with MLL/ENL or E2A/HLF oncogenes. Immortalized cells (5 3 104) from the
third to fifth round of in vitro plating were subsequently transduced with either
GFP- or Cre-GFP-expressing retrovirus. GFP+ cells were sorted, and, then,
relative clonogenic activity was assessed in the additional round of plating.
Leukemogenesis Assays In Vivo
BM progenitors (c-Kit+ cells) were transduced with cMyc-bcl2 together with
GFP or Cre-GFP under identical conditions to those for myeloid progenitor
transformation assays. Infected progenitors (1 3 106) were injected into sub-
lethally irradiated (6.5 Gy) recipients. For the two-step transplantation assay,
BM progenitors transduced with cMyc-bcl2 were injected into recipients as
described above. When transplanted mice exhibited signs of ill health, they
were euthanized and their mononuclear spleen cells were isolated. Leukemic
cells were then transduced with GFP- or Cre-GFP-expressing retroviruses.
Secondary transplantation was performed by injecting 1 3 105 sorted GFP+
cells into sublethally irradiated (6.5 Gy) recipients.
Microarray Analysis and Gene-Expression Analysis of Individuals
with AML
For gene-expression profiling, total RNA was extracted from sorted cells and
amplified (NuGEN Technologies, Inc.). Labeled cDNA was hybridized to the
Mouse Genome 430 2.0 Array (Affymetrix). Normalization and analysis of
chip data were performed using DNA-Chip Analyzer (www.dchip.org) (Li and
Wong, 2001). The expression pattern of the genes in leukemic cells was
assessed using gene-expression data of 285 individuals with AML (http://
www.ncbi.nlm.nih.gov/geo, accession number GSE1159 [NCBI GEO]) (Valk
et al., 2004). See the Supplemental Experimental Procedures for detailed
analysis.
Statistical Analysis
Statistical significance of differences between parameters was assessed us-
ing a two-tailed unpaired t test. The survival distributions were compared using
a log-rank test.
Cell Stem Cell
Regulation of Normal and Leukemic Cells by Evi-1ACCESSION NUMBERS
All microarray data have been deposited in NCBI’s Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO
Series accession number GSE11557.
SUPPLEMENTAL DATA
Supplemental Data for this article include 20 figures, 2 tables, and Supplemen-
tal Experimental Procedures and can be found with this article online at http://
www.cellstemcell.com/cgi/content/full/3/2/207/DC1/.
ACKNOWLEDGMENTS
We thank T. Kitamura for Plat-E packaging cells and pMXs retroviral vector; H.
Nakauchi and M. Onodera for pGCDNsam-eGFP retroviral vector; T. Nakano
for OP9 stromal cells; R. Ono and T. Nosaka for MLL/ENL cDNA; T. Inaba for
E2A/HLF cDNA; R. Sprengel for iCre cDNA; M.H. Tomasson for cMyc-bcl2
cDNA; N. Watanabe, Y. Kato, and A. Iwama for technical advice; R. Takizawa
for help with the generation of Evi-1 mutant mice; Y. Shimamura and Y. Sawa-
moto for expert technical assistance; and Kirin Brewery Pharmaceutical
Research Laboratory for cytokines. This work was supported in part by
a Grant-in-Aid for Scientific Research from the Japan Society for the Promo-
tion of Science and by Health and Labour Sciences Research grants from
the Ministry of Health, Labour and Welfare.
Received: August 30, 2007
Revised: January 5, 2008
Accepted: June 5, 2008
Published: August 6, 2008
REFERENCES
Ayton, P.M., and Cleary, M.L. (2003). Transformation ofmyeloid progenitors by
MLL oncoproteins is dependent on Hoxa7 and Hoxa9. Genes Dev. 17, 2298–
2307.
Barjesteh van Waalwijk van Doorn-Khosrovani, S., Erpelinck, C., van Putten,
W.L., Valk, P.J., van der Poel-van de Luytgaarde, S., Hack, R., Slater, R.,
Smit, E.M., Beverloo, H.B., Verhoef, G., et al. (2003). High EVI1 expression pre-
dicts poor survival in acute myeloid leukemia: a study of 319 de novo AML
patients. Blood 101, 837–845.
Bonnet, D., and Dick, J.E. (1997). Human acute myeloid leukemia is organized
as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3,
730–737.
Bordereaux, D., Fichelson, S., Tambourin, P., and Gisselbrecht, S. (1990).
Alternative splicing of the Evi-1 zinc finger gene generates mRNAs which differ
by the number of zinc finger motifs. Oncogene 5, 925–927.
Buonamici, S., Li, D., Chi, Y., Zhao, R., Wang, X., Brace, L., Ni, H., Saunthar-
arajah, Y., and Nucifora, G. (2004). EVI1 induces myelodysplastic syndrome in
mice. J. Clin. Invest. 114, 713–719.
Calmels, B., Ferguson, C., Laukkanen, M.O., Adler, R., Faulhaber, M., Kim,
H.J., Sellers, S., Hematti, P., Schmidt, M., von Kalle, C., et al. (2005). Recurrent
retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate
hematopoietic cells. Blood 106, 2530–2533.
Delwel, R., Funabiki, T., Kreider, B.L., Morishita, K., and Ihle, J.N. (1993). Four
of the seven zinc fingers of the Evi-1 myeloid-transforming gene are required
for sequence-specific binding to GA(C/T)AAGA(T/C)AAGATAA. Mol. Cell.
Biol. 13, 4291–4300.
Fears, S., Mathieu, C., Zeleznik-Le, N., Huang, S., Rowley, J.D., and Nucifora,
G. (1996). Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as
well as in myeloid leukemia and produces a new member of the PR domain
family. Proc. Natl. Acad. Sci. USA 93, 1642–1647.
Goyama, S., Yamaguchi, Y., Imai, Y., Kawazu, M., Nakagawa, M., Asai, T.,
Kumano, K., Mitani, K., Ogawa, S., Chiba, S., et al. (2004). The transcriptionally
active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region. Blood 104,
3558–3564.
Hirai, H. (1999). The transcription factor Evi-1. Int. J. Biochem. Cell Biol. 31,
1367–1371.
Hoyt, P.R., Bartholomew, C., Davis, A.J., Yutzey, K., Gamer, L.W., Potter, S.S.,
Ihle, J.N., and Mucenski, M.L. (1997). The Evi1 proto-oncogene is required at
midgestation for neural, heart, and paraxial mesenchyme development. Mech.
Dev. 65, 55–70.
Huntly, B.J., and Gilliland, D.G. (2005). Leukaemia stem cells and the evolution
of cancer-stem-cell research. Nat. Rev. Cancer 5, 311–321.
Izutsu, K., Kurokawa, M., Imai, Y., Maki, K., Mitani, K., and Hirai, H. (2001). The
corepressor CtBP interacts with Evi-1 to repress transforming growth factor
beta signaling. Blood 97, 2815–2822.
Jin, G., Yamazaki, Y., Takuwa, M., Takahara, T., Kaneko, K., Kuwata, T.,
Miyata, S., and Nakamura, T. (2007). Trib1 and Evi1 cooperate with Hoxa
and Meis1 in myeloid leukemogenesis. Blood 109, 3998–4005.
Kitamura, T., Koshino, Y., Shibata, F., Oki, T., Nakajima, H., Nosaka, T., and
Kumagai, H. (2003). Retrovirus-mediated gene transfer and expression clon-
ing: powerful tools in functional genomics. Exp. Hematol. 31, 1007–1014.
Kurokawa, M., Mitani, K., Irie, K., Matsuyama, T., Takahashi, T., Chiba, S.,
Yazaki, Y., Matsumoto, K., and Hirai, H. (1998). The oncoprotein Evi-1
represses TGF-beta signalling by inhibiting Smad3. Nature 394, 92–96.
Kurokawa, M., Mitani, K., Yamagata, T., Takahashi, T., Izutsu, K., Ogawa, S.,
Moriguchi, T., Nishida, E., Yazaki, Y., and Hirai, H. (2000). The evi-1 oncopro-
tein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death.
EMBO J. 19, 2958–2968.
Kustikova, O., Fehse, B., Modlich, U., Yang, M., Dullmann, J., Kamino, K., von
Neuhoff, N., Schlegelberger, B., Li, Z., and Baum, C. (2005). Clonal dominance
of hematopoietic stem cells triggered by retroviral gene marking. Science 308,
1171–1174.
Lessard, J., and Sauvageau, G. (2003). Bmi-1 determines the proliferative
capacity of normal and leukaemic stem cells. Nature 423, 255–260.
Li, C., andWong,W.H. (2001). Model-based analysis of oligonucleotide arrays:
expression index computation and outlier detection. Proc. Natl. Acad. Sci.
U.S.A. 98, 31–36.
Li, Z., Chen, M.J., Stacy, T., and Speck, N.A. (2006). Runx1 function in hema-
topoiesis is required in cells that express Tek. Blood 107, 106–110.
Luo, H., Li, Q., O’Neal, J., Kreisel, F., Le Beau, M.M., and Tomasson, M.H.
(2005). c-Myc rapidly induces acute myeloid leukemia in mice without evi-
dence of lymphoma-associated antiapoptotic mutations. Blood 106, 2452–
2461.
Morishita, K., Parganas, E., Parham, D.M., Matsugi, T., and Ihle, J.N. (1990).
The Evi-1 zinc finger myeloid transforming gene is normally expressed in the
kidney and in developing oocytes. Oncogene 5, 1419–1423.
Morishita, K., Parganas, E., Matsugi, T., and Ihle, J.N. (1992). Expression of the
Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentia-
tion in response to granulocyte colony-stimulating factor. Mol. Cell. Biol. 12,
183–189.
Mucenski, M.L., Taylor, B.A., Ihle, J.N., Hartley, J.W., Morse, H.C., 3rd,
Jenkins, N.A., and Copeland, N.G. (1988). Identification of a common eco-
tropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors.
Mol. Cell. Biol. 8, 301–308.
Nitta, E., Izutsu, K., Yamaguchi, Y., Imai, Y., Ogawa, S., Chiba, S., Kurokawa,
M., and Hirai, H. (2005). Oligomerization of Evi-1 regulated by the PR domain
contributes to recruitment of corepressor CtBP. Oncogene 24, 6165–6173.
Ogawa, S., Mitani, K., Kurokawa, M., Matsuo, Y., Minowada, J., Inazawa, J.,
Kamada, N., Tsubota, T., Yazaki, Y., and Hirai, H. (1996). Abnormal expression
of Evi-1 gene in human leukemias. Hum. Cell 9, 323–332.
Ott, M.G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U.,
Glimm, H., Kuhlcke, K., Schilz, A., Kunkel, H., et al. (2006). Correction of
X-linked chronic granulomatous disease by gene therapy, augmented by
insertional activation of MDS1–EVI1, PRDM16 or SETBP1. Nat. Med. 12,
401–409.
Cell Stem Cell 3, 207–220, August 7, 2008 ª2008 Elsevier Inc. 219
Cell Stem Cell
Regulation of Normal and Leukemic Cells by Evi-1Perkins, A.S., Fishel, R., Jenkins, N.A., andCopeland, N.G. (1991). Evi-1, amu-
rine zinc finger proto-oncogene, encodes a sequence-specific DNA-binding
protein. Mol. Cell. Biol. 11, 2665–2674.
Pintado, T., Ferro, M.T., San Roman, C., Mayayo, M., and Larana, J.G. (1985).
Clinical correlations of the 3q21;q26 cytogenetic anomaly. A leukemic or
myelodysplastic syndrome with preserved or increased platelet production
and lack of response to cytotoxic drug therapy. Cancer 55, 535–541.
Smith, K.S., Rhee, J.W., and Cleary, M.L. (2002). Transformation of bone mar-
row B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2. Mol. Cell.
Biol. 22, 7678–7687.
Sood, R., Talwar-Trikha, A., Chakrabarti, S.R., and Nucifora, G. (1999). MDS1/
EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory ef-
fect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product
of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Leukemia
13, 348–357.
Sugita, M., Tanaka, N., Davidson, S., Sekiya, S., Varella-Garcia, M., West, J.,
Drabkin, H.A., and Gemmill, R.M. (2000). Molecular definition of a small ampli-
fication domain within 3q26 in tumors of cervix, ovary, and lung. Cancer Genet.
Cytogenet. 117, 9–18.220 Cell Stem Cell 3, 207–220, August 7, 2008 ª2008 Elsevier Inc.Suzukawa, K., Parganas, E., Gajjar, A., Abe, T., Takahashi, S., Tani, K., Asano,
S., Asou, H., Kamada, N., Yokota, J., et al. (1994). Identification of a breakpoint
cluster region 30 of the ribophorin I gene at 3q21 associated with the transcrip-
tional activation of the EVI1 gene in acute myelogenous leukemias with
inv(3)(q21q26). Blood 84, 2681–2688.
Tanaka, T., Nishida, J., Mitani, K., Ogawa, S., Yazaki, Y., and Hirai, H. (1994).
Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with
dependence on the second zinc finger domain. J. Biol. Chem. 269, 24020–
24026.
Valk, P.J., Verhaak, R.G., Beijen, M.A., Erpelinck, C.A., Barjesteh vanWaalwijk
van Doorn-Khosrovani, S., Boer, J.M., Beverloo, H.B., Moorhouse, M.J., van
der Spek, P.J., Lowenberg, B., et al. (2004). Prognostically useful gene-ex-
pression profiles in acute myeloid leukemia. N. Engl. J. Med. 350, 1617–1628.
Yuasa, H., Oike, Y., Iwama, A., Nishikata, I., Sugiyama, D., Perkins, A., Mucen-
ski, M.L., Suda, T., and Morishita, K. (2005). Oncogenic transcription factor
Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expres-
sion. EMBO J. 24, 1976–1987.
Zhang, C.C., and Lodish, H.F. (2005). Murine hematopoietic stem cells change
their surface phenotype during ex vivo expansion. Blood 105, 4314–4320.
